These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19800620)

  • 21. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study.
    Papanikolaou EG; Verpoest W; Fatemi H; Tarlatzis B; Devroey P; Tournaye H
    Fertil Steril; 2011 Mar; 95(3):1174-7. PubMed ID: 20979997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GnRH agonist triggering: recent developments.
    Kol S; Humaidan P
    Reprod Biomed Online; 2013 Mar; 26(3):226-30. PubMed ID: 23337420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Application of gonadotropin-releasing hormone agonist for triggering ovulation in high risk gonadotropin stimulating cycles of infertile polycystic ovary syndrome patients].
    Dong H; Chen S; Xing F
    Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):94-6. PubMed ID: 11263206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study.
    Griesinger G; Berndt H; Schultz L; Schultze-Mosgau A; Diedrich K; von Otte S
    Reprod Biomed Online; 2011 Feb; 22(2):133-9. PubMed ID: 21227753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression.
    Bermejo A; Cerrillo M; Ruiz-Alonso M; Blesa D; Simón C; Pellicer A; Garcia-Velasco JA
    Fertil Steril; 2014 Jan; 101(1):138-146.e3. PubMed ID: 24182413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related.
    Shapiro BS; Andersen CY
    Fertil Steril; 2015 Apr; 103(4):874-8. PubMed ID: 25707333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian hyperstimulation syndrome prevention strategies: oral contraceptive pills-dual gonadotropin-releasing hormone agonist suppression with step-down gonadotropin protocols.
    Damario MA
    Semin Reprod Med; 2010 Nov; 28(6):468-74. PubMed ID: 21082505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.
    Kol S
    Fertil Steril; 2004 Jan; 81(1):1-5. PubMed ID: 14711532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.
    Tsakiridis I; Najdecki R; Tatsi P; Timotheou E; Kalinderi K; Michos G; Virgiliou A; Yarali H; Athanasiadis A; Papanikolaou EG
    JBRA Assist Reprod; 2020 Oct; 24(4):436-441. PubMed ID: 32489086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH.
    Martínez F; Boada M; Coroleu B; Clua E; Parera N; Rodríguez I; Barri PN
    Hum Reprod; 2006 Aug; 21(8):2121-5. PubMed ID: 16632462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GnRH agonist long protocol vs. a single 3-mg gnRH antagonist: a comparison of 2 protocols for pituitary down-regulation in oocyte donor-controlled ovarian hyperstimulation cycles.
    Erb TM; Wakim AN
    J Reprod Med; 2008 May; 53(5):331-7. PubMed ID: 18567278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases.
    Nikolettos N; Asimakopoulos B; Simopoulou M; al-Hasani S
    In Vivo; 2003; 17(6):655-8. PubMed ID: 14758735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How to prevent completely ovarian hyperstimulation with GnRH-based stimulation protocols].
    Kol S
    Akush Ginekol (Sofiia); 2001; 40(4):36-41. PubMed ID: 11803870
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.